Joseph Icenogle Selected Research

Granuloma

4/2024	Neutralization of Rubella Vaccine Virus and Immunodeficiency-Related Vaccine-Derived Rubella Viruses by Intravenous Immunoglobulins.
3/2022	Drug Sensitivity of Vaccine-Derived Rubella Viruses and Quasispecies Evolution in Granulomatous Lesions of Two Ataxia-Telangiectasia Patients Treated with Nitazoxanide.
1/2022	Case report: Persistent shedding of a live vaccine-derived rubella virus in a young man with severe combined immunodeficiency and cutaneous granuloma.
7/2021	Granulomatous Dermatitis Associated With Rubella Virus Infection in an Adult With Immunodeficiency.
1/2021	Rubella Virus Infected Macrophages and Neutrophils Define Patterns of Granulomatous Inflammation in Inborn and Acquired Errors of Immunity.
12/2020	Rubella virus-associated chronic inflammation in primary immunodeficiency diseases.
10/2019	Infectious vaccine-derived rubella viruses emerge, persist, and evolve in cutaneous granulomas of children with primary immunodeficiencies.
1/2019	Outcomes for Nitazoxanide Treatment in a Case Series of Patients with Primary Immunodeficiencies and Rubella Virus-Associated Granuloma.
11/2017	Inhibition of rubella virus replication by the broad-spectrum drug nitazoxanide in cell culture and in a patient with a primary immune deficiency.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Joseph Icenogle Research Topics

Disease

21	Rubella (German Measles) 04/2024 - 12/2005
9	Granuloma 04/2024 - 11/2017
6	Infections 04/2024 - 01/2009
6	Measles 01/2022 - 12/2005
3	Exanthema (Rash) 10/2016 - 01/2009
3	Congenital Rubella Syndrome (Syndrome, Congenital Rubella) 09/2016 - 12/2005
2	Primary Immunodeficiency Diseases 04/2024 - 11/2017
2	Mumps 01/2022 - 01/2020
2	Inflammation (Inflammations) 01/2021 - 12/2020
1	Ataxia Telangiectasia (Louis Bar Syndrome) 03/2022
1	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 01/2022
1	X-Linked Combined Immunodeficiency Diseases (X Linked Severe Combined Immunodeficiency) 01/2022
1	Parasitic Diseases (Parasitic Disease) 11/2017
1	Perinatal Death 09/2016
1	Stillbirth 09/2016
1	Vascular System Injuries 01/2016
1	Fever (Fevers) 12/2014

Drug/Important Bio-Agent (IBA)

13	VaccinesIBA 04/2024 - 12/2005
6	RNA (Ribonucleic Acid)IBA 03/2022 - 01/2009
6	Immunoglobulin M (IgM)IBA 11/2018 - 01/2009
5	AntigensIBA 01/2021 - 01/2016
3	nitazoxanide (NTZ)FDA Link 03/2022 - 11/2017
3	Measles-Mumps-Rubella Vaccine (MMR Vaccine)IBA 01/2022 - 01/2019
2	EnzymesIBA 01/2020 - 11/2018
2	Immunoglobulin G (IgG)IBA 01/2020 - 01/2020
2	ImmunosorbentsIBA 01/2020 - 11/2018
2	AntibodiesIBA 11/2018 - 01/2009
1	Rubella VaccineIBA 04/2024
1	Immunoglobulins (Immunoglobulin)IBA 04/2024
1	Intravenous Immunoglobulins (IVIG)FDA Link 04/2024
1	Immunosuppressive Agents (Immunosuppressants)IBA 07/2021
1	SteroidsIBA 01/2021
1	Viral RNAIBA 12/2020
1	Neutralizing AntibodiesIBA 01/2020
1	Membrane Glycoproteins (Membrane Glycoprotein)IBA 11/2017
1	Antiviral Agents (Antivirals)IBA 11/2017
1	Proteins (Proteins, Gene)FDA Link 12/2016
1	Amino Acids FDA Link 12/2016
1	Intergenic DNA (Junk DNA)IBA 12/2014
1	NucleotidesIBA 12/2014

Therapy/Procedure

2	Therapeutics 04/2024 - 11/2017
2	Salvage Therapy 03/2022 - 01/2019
1	Cell Transplantation 01/2021
1	Hematopoietic Stem Cell Transplantation 12/2020